Table 1.
Basal clinicopathological characteristics of 293 HCC patients with Microvascular Invasion with and without adjuvant Lenvatinib.
| Variable | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
| No Lenvatinib (n = 236) | Lenvatinib (n = 57) | P | No Lenvatinib (n = 57) | Lenvatinib (n = 57) | P | |
| Age | 52 (21-69) | 53 (20-70) | 0.265 | 52 (21-69) | 53 (20-70) | 0.135 |
| Gender | 0.073 | 0.178 | ||||
| Female | 213 (90.3) | 46 (80.7) | 52 (91.2) | 46 (80.7) | ||
| Male | 23 (9.75) | 11 (19.3) | 5 (8.77) | 11 (19.3) | ||
| HBV-DNA, IU/mL | 0.004 | 1.000 | ||||
| ≤2000 | 105 (44.5) | 38 (66.7) | 37 (64.9) | 38 (66.7) | ||
| >2000 | 131 (55.5) | 19 (33.3) | 20 (35.1) | 19 (33.3) | ||
| TBIL, μmol/L | 0.399 | 1.000 | ||||
| ≤17 | 162 (68.6) | 43 (75.4) | 44 (77.2) | 43 (75.4) | ||
| >17 | 74 (31.4) | 14 (24.6) | 13 (22.8) | 14 (24.6) | ||
| ALB, g/L | 0.258 | 0.679 | ||||
| ≤35 | 8 (3.39) | 4 (7.02) | 2 (3.51) | 4 (7.02) | ||
| >35 | 228 (96.6) | 53 (93.0) | 55 (96.5) | 53 (93.0) | ||
| ALT, U/L | 0.195 | 0.702 | ||||
| ≤44 | 124 (52.5) | 36 (63.2) | 33 (57.9) | 36 (63.2) | ||
| >44 | 112 (47.5) | 21 (36.8) | 24 (42.1) | 21 (36.8) | ||
| PLT, *109/ml | 1.000 | 0.178 | ||||
| ≤100 | 44 (18.6) | 11 (19.3) | 5 (8.77) | 11 (19.3) | ||
| >100 | 192 (81.4) | 46 (80.7) | 52 (91.2) | 46 (80.7) | ||
| PT, S | 0.032 | 1.000 | ||||
| ≤13 | 183 (77.5) | 52 (91.2) | 53 (93.0) | 52 (91.2) | ||
| >13 | 53 (22.5) | 5 (8.77) | 4 (7.02) | 5 (8.77) | ||
| NLR | 0.614 | 0.064 | ||||
| ≤2.4 | 159 (67.4) | 41 (71.9) | 29 (50.9) | 37 (64.9) | ||
| >2.4 | 77 (32.6) | 16 (28.1) | 28 (49.1) | 20 (35.1) | ||
| AFP, ng/mL | 0.007 | 1.000 | ||||
| ≤400 | 88 (37.3) | 33 (57.9) | 33 (57.9) | 33 (57.9) | ||
| >400 | 148 (62.7) | 24 (42.1) | 24 (42.1) | 24 (42.1) | ||
| Transfusion | 0.378 | 0.164 | ||||
| No | 157 (66.5) | 42 (73.7) | 34 (59.6) | 42 (73.7) | ||
| Yes | 79 (33.5) | 15 (26.3) | 23 (40.4) | 15 (26.3) | ||
| Tumor diameter, cm | 0.515 | 1.000 | ||||
| ≤5 | 54 (22.9) | 16 (28.1) | 17 (29.8) | 16 (28.1) | ||
| >5 | 182 (77.1) | 41 (71.9) | 40 (70.2) | 41 (71.9) | ||
| Tumor number | 0.389 | 0.823 | ||||
| 1 | 200 (84.7) | 45 (78.9) | 43 (75.4) | 45 (78.9) | ||
| ≥2 | 36 (15.3) | 12 (21.1) | 14 (24.6) | 12 (21.1) | ||
| Microvascular invasion | 0.049 | 1.000 | ||||
| M1 | 168 (71.1) | 31 (54.3) | 33 (57.8) | 31 (54.3) | ||
| M2 | 68 (28.9) | 26 (45.7) | 24 (42.2) | 26 (45.7) | ||
| Tumor capsule | 0.770 | 1.000 | ||||
| Complete | 129 (54.7) | 33 (57.9) | 32 (56.1) | 33 (57.9) | ||
| Incomplete | 107 (45.3) | 24 (42.1) | 25 (43.9) | 24 (42.1) | ||
| Margin | 0.283 | 0.430 | ||||
| Narrow | 91 (38.6) | 17 (29.8) | 22 (38.6) | 17 (29.8) | ||
| Wide | 145 (61.4) | 40 (70.2) | 35 (61.4) | 40 (70.2) | ||
| Edmondson-Steiner grade | 0.096 | 1.000 | ||||
| I-II | 10 (4.24) | 6 (10.5) | 5 (8.77) | 6 (10.5) | ||
| III-VI | 226 (95.8) | 51 (89.5) | 52 (91.2) | 51 (89.5) | ||
| Cirrhosis | 1.000 | 0.254 | ||||
| No | 85 (36.0) | 20 (35.1) | 27 (47.4) | 20 (35.1) | ||
| Yes | 151 (64.0) | 37 (64.9) | 30 (52.6) | 37 (64.9) | ||
Bold values indicate statistical significance (P < 0.05).
HCC, Hepatocellular Carcinoma; PSM, propensity score matching. HBV-DNA, hepatitis B virus-deoxyribonucleic acid; TBIL, total bilirubin; ALB, albumin; ALT, Alanine aminotransferase; PT, Prothrombin time; PLT, platelet; NLR, neutrophil‐to‐lymphocyte ratio; AFP, alpha fetoprotein.